Cibc World Markets Corp Takes $145,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Cibc World Markets Corp bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 19,338 shares of the biotechnology company’s stock, valued at approximately $145,000.

Other hedge funds have also added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $412,000. Charles Schwab Investment Management Inc. increased its stake in shares of BioCryst Pharmaceuticals by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company’s stock worth $14,349,000 after buying an additional 102,860 shares during the period. Fisher Asset Management LLC raised its holdings in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after buying an additional 481,359 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after buying an additional 86,571 shares during the period. Finally, FMR LLC grew its holdings in BioCryst Pharmaceuticals by 2.4% in the 3rd quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock worth $15,112,000 after acquiring an additional 46,110 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Up 0.4 %

NASDAQ BCRX opened at $7.83 on Friday. The firm has a market capitalization of $1.64 billion, a PE ratio of -12.84 and a beta of 1.85. The stock’s 50 day moving average is $8.17 and its 200 day moving average is $7.82. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The company’s quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 EPS. On average, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BCRX shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Needham & Company LLC increased their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Evercore ISI raised their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.